CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).

Russell Kent  Pachynski

Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Dendreon; EMD Serono; Genomic Health; Jounce Therapeutics; Pfizer/EMD Serono; Sanofi

Speakers' Bureau - AstraZeneca; Dendreon; Genentech/Roche; Genomic Health; Merck; Sanofi

Research Funding - Janssen Oncology

Travel, Accommodations, Expenses - Genentech/Roche

Margitta  Retz

No Relationships to Disclose

Jeffrey C.  Goh

Stock and Other Ownership Interests  - Immutep

Honoraria - Ipsen

Consulting or Advisory Role - AstraZeneca; Tesaro

Speakers' Bureau - AstraZeneca; Ipsen; Janssen; Mundipharma; Novartis

Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca

Mauricio  Burotto

No Relationships to Disclose

Gwenaelle  Gravis

Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); IPSEN (Inst); Janssen (Inst); MSD Oncology (Inst); Pfizer (Inst); Sanofi/Aventis (Inst)

Speakers' Bureau - Amgen (Inst); Astellas Pharma (Inst); BMS (Inst); Ipsen (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Sanofi/Aventis (Inst)

Research Funding - BMS (Inst)

Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Pfizer; Sanofi

Daniel  Castellano

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi; Sanofi

Research Funding - Janssen Oncology (Inst)

Travel, Accommodations, Expenses - AstraZeneca Spain; Bristol-Myers Squibb; Pfizer; Roche

Aude  Flechon

Honoraria - Astellas Pharma; AstraZeneca; Bayer; BMS; Ipsen; Janssen-Cilag; MSD Oncology; PFIZER; Roche/Genentech; Sanofi/Aventis

Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; BMS; IPSEN; Janssen-Cilag; MSD Oncology; Pfizer; Roche/Genentech; Sanofi/Aventis

Stefanie  Zschaebitz

Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Eisai; EUSA Pharma; Merck; MSD Oncology; Pfizer; Roche; Sanofi/Aventis (Inst)

Research Funding - Eisai (Inst)

Travel, Accommodations, Expenses - Merck

David R.  Shaffer

No Relationships to Disclose

Juan Carlos  Vazquez Limon

Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD

Consulting or Advisory Role - AstraZeneca; Roche

Research Funding - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Sanofi

Travel, Accommodations, Expenses - Asofarma; AstraZeneca; Pfizer

(OPTIONAL) Uncompensated Relationships - Roche

Marc-Oliver  Grimm

Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Medac; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Merck Serono; MSD; Ono Pharmaceutical; Pfizer

Research Funding - Bristol-Myers Squibb (Inst); Intuitive Surgical (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono

Steven L.  McCune

Speakers' Bureau - Bristol-Myers Squibb

Research Funding - Bristol-Myers Squibb; Roche/Genentech

Other Relationship - Roche (Inst)

Neha P.  Amin

No Relationships to Disclose

Jia  Li

Employment - Bristol-Myers Squibb

Stock and Other Ownership Interests  - Bristol-Myers Squibb

Xuya  Wang

Employment - Bristol Myers Squibb; Daiichi Sankyo (I)

Stock and Other Ownership Interests  - AstraZeneca; Bristol-Myers Squibb; Guardant Health; Illumina

Consulting or Advisory Role - Daiichi Sankyo (I)

Travel, Accommodations, Expenses - Bristol-Myers Squibb

Keziban  Unsal-Kacmaz

Employment - Bristol-Myers Squibb

Stock and Other Ownership Interests  - Bristol-Myers Squibb

Fred  Saad

Honoraria - Abbvie; Astellas Pharma; AstraZeneca; Bayer; Janssen Oncology; Myovant Sciences; Pfizer; Sanofi

Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Myovant Sciences; Pfizer; Sanofi

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Pfizer (Inst); Sanofi (Inst)

Daniel P.  Petrylak

Stock and Other Ownership Interests  - Bellicum Pharmaceuticals; TYME

Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Incyte; Ipsen; Janssen; Janssen; Lilly; Mirati Therapeutics; Monopteros Therapeutics; Pfizer; Pharmacyclics; Roche; Seagen; Urogen pharma

Research Funding - Advanced Accelerator Applications (Inst); Agensys (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Endocyte (Inst); Genentech (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Replimune (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)

Expert Testimony - Celgene; sanofi

Karim  Fizazi

Honoraria - Astellas Pharma (Inst); Bayer; Janssen (Inst); Sanofi (Inst)

Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer; Bristol-Myers Squibb; Clovis Oncology; Curevac; ESSA (Inst); Janssen Oncology (Inst); Orion; Sanofi (Inst)

Travel, Accommodations, Expenses - Janssen; MSD